Olin J, Masand P
Forensic Unit, Colorado Mental Health Institute, at Pueblo.
Psychosomatics. 1996 Jan-Feb;37(1):57-62. doi: 10.1016/S0033-3182(96)71599-2.
The hospital charts of 59 hospitalized oncology patients who had been treated with either dextroamphetamine or methylphenidate for depression during a 5-year period at the Massachusetts General Hospital were examined. Eighty-three percent of the patients showed at least some improvement following psychostimulant treatment. Seventy-three percent of all patients demonstrated marked or moderate depressive symptom improvement. No significant differences in efficacy were noted between the two psychostimulants, or across psychiatric diagnostic categories for depression. The patients improved quickly, usually within the first 2 days of treatment. Ten percent of the patients experienced adverse reactions warranting discontinuation of the psychostimulants. Fifty-four percent of all patients had some appetite improvement. Anorexia was not observed as a treatment side effect. The authors conclude that psychostimulants are an effective and safe method of treatment for the depressed oncology patient.
对麻省总医院59名肿瘤住院患者的病历进行了检查，这些患者在5年期间接受了右旋苯丙胺或哌醋甲酯治疗抑郁症。83%的患者在接受精神兴奋剂治疗后至少有一些改善。所有患者中有73%表现出明显或中度的抑郁症状改善。两种精神兴奋剂之间或抑郁症的不同精神科诊断类别之间在疗效上没有显著差异。患者改善迅速，通常在治疗的头两天内。10%的患者出现不良反应，需要停用精神兴奋剂。所有患者中有54%的食欲有所改善。未观察到厌食作为治疗副作用。作者得出结论，精神兴奋剂是治疗肿瘤抑郁症患者的一种有效且安全的方法。
